We are live on ! Find out more

Ocular Therapeutix

OCUL

Market cap $1.61B

6.97 USD

-0.34

4.65%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

7.03

+0.06

0.86%

1 day

-4.65%

5 days

7.23%

1 month

-9.13%

3 months

-17.71%

6 months

-25.61%

Year to date

-41.03%

1 year

-41.03%

5 years

-1.55%

10 years

23.14%

About: Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Employees: 325

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 23.5%

Neutral 76.5%

Negative 0%

Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences

BEDFORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in November 2026.

Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences

Ocular Therapeutix: The Drug Won, The Stock Lost, And That's The Opportunity

Ocular Therapeutix is rated Buy (speculative) with a 12-month price target of $7.90, reflecting a lopsided risk/reward profile. AXPAXLI's strong Phase 3 SOL-1 results support a clear regulatory path, with NDA filing expected in Q4 and potential 2027 launch. The market is pricing in $1.26 billion in peak U.S. sales for OCUL after competitor advances, lost takeover premium, and rising cash burn.

Ocular Therapeutix: The Drug Won, The Stock Lost, And That's The Opportunity

Ocular Therapeutix, Inc. (OCUL) Discusses Progress and Regulatory Update on AXPAXLI NDA Filing Transcript

Ocular Therapeutix, Inc. (OCUL) Discusses Progress and Regulatory Update on AXPAXLI NDA Filing Transcript

Ocular Therapeutix, Inc. (OCUL) Discusses Progress and Regulatory Update on AXPAXLI NDA Filing Transcript

Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Win

Ocular Therapeutix NASDAQ: OCUL is preparing a fourth-quarter new drug application submission for AXPAXLI, its investigational maintenance treatment for wet age-related macular degeneration, following discussions with the U.S. Food and Drug Administration, President and Chief Executive Officer Pravin Dugel said during a fireside chat.

Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Win

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to fifteen newly hired non-executive employees. The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences

BEDFORD, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in October 2026.

Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences

Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success

Ocular Therapeutix NASDAQ: OCUL said it remains on track to submit a U.S. marketing application for AXPAXLI in the fourth quarter of this year, following what Chief Executive Officer Pravin Dugel described as alignment with the Food and Drug Administration on the company's planned submission package for wet age-related macular degeneration, or wet AMD.

Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to nine newly hired non-executive employees. The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD

Consistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular's plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory evidence AXPAXLI NDA submission for wet AMD remains on track for 4Q 2026 NDA submission to include subjects that have received multiple AXPAXLI injections in support of the Company's application for repeat dosing Commercial readiness accelerates ahead of potential 2027 launch as AXPAXLI is well positioned to potentially be the first TKI approved for wet AMD BEDFORD, Mass., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced the successful completion of its Pre-New Drug Application (NDA) Meeting with the U.S. Food and Drug Administration (FDA) for its investigational product candidate AXPAXLI™ (also known as OTX-TKI) for the treatment of wet age-related macular degeneration (wet AMD).

Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD

Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences

BEDFORD, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in September and October 2026.

Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences

See News Rankings

Price charts implemented using Lightweight Charts™